Brepocitinib (PF-06700841) is a potent dual TYK2/ JAK1 inhibitor that has shown promising results in improving signs and symptoms of dermatological diseases, such as AD and PsO [20, 21]. This evidence concerns the gene TYK2 and Alzheimer disease.